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Psychiatric blood biomarkers: avoiding jumping to premature
negative or positive conclusions
AB Niculescu1,2, D Levey1,3, H Le-Niculescu1, E Niculescu1, SM Kurian4 and D Salomon4
Blood biomarkers may provide a scientiﬁcally useful and clinically usable peripheral signal in psychiatry, as they have been doing
for other ﬁelds of medicine. Jumping to premature conclusions, negative or positive, can create confusion in this ﬁeld.
Reproducibility is a hallmark of good science. We discuss some recent examples from this dynamic ﬁeld, and show some new data
in support of previously published biomarkers for suicidality (SAT1, MARCKS and SKA2). Methodological clarity and rigor in terms of
biomarker discovery, validation and testing is needed. We propose a set of principles for what constitutes a good biomarker, similar
in spirit to the Koch postulates used at the birth of the ﬁeld of infectious diseases.
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… ‘With all thy getting, get understanding’ …
—Proverbs 4:7 King James Version (KJV)
The identiﬁcation of blood biomarkers for disease risk has
emerged as an important area of translational research in medicine,
particularly in cancer1 and cardiovascular medicine,2 in the quest
for precision and individualization of preventive measures and of
treatment. Although genetic tests may have a useful role as well3
and can be done early on in life, biomarkers that look at gene
expression, proteomic or metabolomic characteristics better reﬂect
the gene–environment interactions that lead to disease manifesta-
tion. In psychiatry, in particular, it is impractical to directly access the
target organ—the brain—in live individuals, and even its proxy
ﬂuid, the cerebrospinal ﬂuid, is less accessible for routine use than
the blood. Although it is clear that the blood is not the brain, there
are common biological mechanisms, environmental and medica-
tion effects across tissues that can be identiﬁed with convergent
approaches.4,5 Upon demonstration of reproducibility and predic-
tive ability in independent cohorts, the key litmus tests, such
biomarkers should be rapidly moved into population testing and
validation for clinical use. The unmet need in psychiatry is great,
and the potential of biomarkers to revolutionize clinical manage-
ment is commensurate with that. However, the burden of proof
needs to be high as well.
We have recently published a study detailing the identiﬁcation of
blood gene expression biomarkers for suicidality.6 The discovery was
carried out using a powerful but hard to accomplish longitudinal
within-subject design in male bipolar subjects, a high-risk group for
suicide, identifying a small but very valuable subgroup of subjects
who exhibited major switches in suicidal ideation at the time of
different testing visits. Differential gene expression studies within
each subject were carried out, factoring out any genetic and a
majority of environmental effects. (Self-)report of phenotype is also
more accurate in a within-subject design. In the effect, this design is
arguably better than an identical twin study. What was changed in
expression in common across the different subjects was carried
forward in the analysis. A convergent functional genomics (CFG)
approach was then used to prioritize the differentially expressed
gene list, using independent lines of evidence implicating them in
suicide (human genetic studies, human postmortem brain studies).
Validation of the genes prioritized by CFG was carried out by testing
for changes in expression in the blood of a demographically
matched for gender and age cohort of male violent (non-overdose)
suicide completers from the coroners’ ofﬁce. Six genes (SAT1,
MARCKS, UBA6, PTEN, MAP3K and MT-ND6) showed a statistically
signiﬁcant, Bonferroni corrected, stepwise change in expression
from live bipolar subjects in no suicidal states to high suicidal states
to suicide completers. To further validate the markers and
demonstrate their predictive ability, we examined in a larger male
bipolar cohort whether biomarker levels can predict future
psychiatric hospitalizations for suicidality, and demonstrated that
they did. The panel of six markers had an AUC of 0.73, and a P-value
of 0.04. This work has opened the ﬁeld to active exploration, and
raised hopes for progress. What was not known at the time, and is
an area of active exploration by us and others, was: (1) whether
these biomarkers work in diagnoses other than bipolar disorder or
there are other biomarkers better suited for other diagnoses, (2)
whether gender has a role, that is, would a different set of
biomarkers work in females and (3) whether type of suicide (violent
vs non-violent and impulsive vs planned) is underpinned by
different sets of markers. The answer to these questions is likely to
be at least partially yes. Gene expression is powerfully modulated by
disease biology and medication effects in the ﬁrst instance, by
gender biology and sex hormones in the second instance, and by
stress reactivity, drug abuse and toxicology in the third instance.
Since the publication of our work in 2013, a study by Weinberger
and colleagues7 has replicated one of our six markers, MARCKS, in
the brains of male violent suicide completers with schizophrenia,
but not those with depression or with non-violent suicide. Another
study by Kaminsky and colleagues8 identiﬁed a new biomarker for
suicide, SKA2, primarily in depression cohorts. Interestingly, SKA2
has effects upstream of our top biomarkers, SAT1, and may regulate
its transcription.
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Figure 1. Reproducibility and diagnostic differences for top biomarkers for suicidality. Methods are as previously described.6 Demographics of
cohorts are presented in Supplementary Table S1. SAT1 and MARCKS, previously identiﬁed as top blood biomarkers increased in expression in
suicidality by our group,6 are signiﬁcantly increased in violent suicide completers and in live subjects with high suicidal ideation (SI) in bipolar
disorder, but not depression. SKA2, previously identiﬁed as a blood biomarker decreased in expression in suicidality by Kaminsky and
colleagues,8 is signiﬁcantly decreased in violent suicide completers.
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A study just reported by Mullins et al.9 purports not to replicate our
six top biomarkers. The authors jump to the conclusion of wanting to
make a general statement in that regard. However, the study was
carried out: (1) in depression as opposed to our bipolar work, (2) in a
cohort that was 75% female as opposed to our exclusively male
cohorts and (3) in a different phenotype/type of suicidality (treatment
emergent suicidal ideation in response to antidepressant treatment).
Moreover, the probands and controls were not matched for age
(P-value for age difference was signiﬁcant at P=0.02). That may not
matter much in the genetic (DNA) research arena in which the senior
study authors have a good prior track record and expertise. For gene
expression (RNA), however, age matters. Particularly unfortunate,
given the fact that their sample was 75% females and thus female sex
hormones come into play in terms of effects on gene expression, is
the fact that their probands were on average menopausal, and their
controls on average pre-menopausal. Thus, these data are hard to rely
upon, and general conclusions based on it are unwarranted.
That being said, better designed biomarker discovery and
validation studies in depression, in females, and in other types of
suicidality are areas that should be encouraged and vigorously
pursued. Our group and others are actively working on this. It
seems clear that there may be differences between bipolar
disorder and depression, as shown here in Figure 1, where we
reproduce in larger cohorts our previous ﬁndings of increased
SAT1 and MARCKS,6 as well as independently reproduce the
decreased SKA2 ﬁnding reported by Kaminsky and colleagues,8
more so in bipolar disorder than in depression.
An example of possible premature jumping to positive
conclusions was also published recently. Redei et al.10 purport to
have identiﬁed biomarkers for depression. These biomarkers were
originally discovered in an animal model, of limited direct relevance
or speciﬁcity to the human condition. There is a relative lack of
transparency of why certain biomarkers were chosen and not others
to carry forward in the current human study reported. Although
there are some differences reported, there is no clear validation in
independent human cohorts of a locked panel of markers, nor data
on predictive ability for clinical course of the disorder in inde-
pendent cohorts. In contrast, a panel of 10 biomarkers for mood
state discovered by us in human studies of bipolar disorder subjects,
locked and then validated by us in independent cohorts before
publication,4 was recently replicated completely independently by
another group and shown to track the course of response to
cognitive–behavioral therapy in depression.11
Moving forward, it may be useful for our ﬁeld to have a set of rules or
postulates for what constitute good biomarkers, similar to the Koch
postulates used in infectious diseases. First, working on the right
problem. One has to be clear about the population used for discovery:
for which well-deﬁned phenotype, in what clinical diagnostic group, of
what gender, the biomarker(s) have been discovered. Second, using the
right approach. The experimental design used to discover biomarkers is
crucial for signal detection. A within-subject design is more powerful
than a case–case design with extremes of distribution, which in turn is
more powerful than a case–control design, that would require a much
higher number of subjects. Metabolomics might bemore direct12 (albeit
more limited) than proteomics, which in turn, if used in an unbiased
discovery fashion,13 may be more powerful than gene expression,
which in turn is more powerful than genetics, as thousands of single-
nucleotide polymorphisms can converge in the regulation of expression
of a gene. A convergent functional genomics3–6 or integrative approach
to prioritize biomarkers based on multiple prior lines of evidence would
ensure a ﬁt to disease rather than a ﬁt to cohort that may occur with
machine learning approaches. Third, demonstrating reproducibility the
right way. The validation of an a priori selected biomarker or locked
panel of biomarkers in non-overlapping, completely independent
cohorts with robust phenotypes is a must before making any believable
claims. Fourth, the right use of the biomarkers. Showing prospectively
that the biomarker(s) have predictive ability for future clinical course is
necessary for the ﬁeld to start adopting the biomarkers and to begin
translating them into clinical practice, which should be a clear and
present goal for all engaged in this type of research.
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